ClinicalTrials.gg
TerminatedNCT03833167Updated Sep 28, 2026Results posted

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

A Phase 3 interventional study of Pembrolizumab and Placebo in Carcinoma, Squamous Cell, sponsored by Merck Sharp & Dohme LLC. Terminated at 181 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study stopped due to futility
Updated Sep 28, 2026Now TerminatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing pembrolizumab in Carcinoma, Squamous Cell — 3 open to participants now, 7 under way, none of them phase 3. pembrolizumab · Carcinoma, Squamous Cell.

Enrollment
3rd of 17
450 · median 48
Started
2019
the only one that year
Phase 3
2 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
4 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing pembrolizumab in Carcinoma, Squamous Cell, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 3, and was the 8th registered.

Carcinoma, Squamous Cell

628 studies on the registry are indexed under Carcinoma, Squamous Cell; 134 are open to participants now.

Browse Carcinoma, Squamous Cell studies →

Open to participants now

3 of the 17 studies testing pembrolizumab in Carcinoma, Squamous Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Carcinoma, Squamous Cell studies recruiting now, 86 (84%) set no upper age limit and 8 (8%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pembrolizumab in Carcinoma, Squamous Cell, or all of them as a file.
02

Study summary

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).

03

Conditions studied

  • Carcinoma, Squamous Cell

Keywords

  • Programmed Cell Death-1 (PD-1)
  • Programmed Cell Death 1
  • PD1
  • Programmed Cell Death Ligand 1 (PD-L1)
  • Programmed Cell Death Ligand 2 (PD-L2)
  • PDL1
  • PDL2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion Criteria include, but are not limited to:

  • Has confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of ( skin involvement from another type of primary cancer or from an unknown primary cancer is not permitted)
  • Has histologically confirmed locally advanced cutaneous squamous cell carcinoma (LA cSCC) with ≥1 high-risk feature(s) as the primary site of malignancy
  • Has undergone complete macroscopic resection of all known cSCC disease with or without microscopic positive margins. For those participants with residual microscopic positive margin involvement, confirmation that additional re-excision is not possible must be provided
  • Has completed radiotherapy (RT) for LA cSCC with last dose of RT ≥4 weeks and ≤16 weeks from randomization
  • Has received an adequate post-op dose of RT (either hypofractionated or conventional)
  • Is disease free as assessed by the investigator with complete radiographic staging assessment ≤28 days from randomization
  • Is not pregnant or breastfeeding
  • Is not a person of (POCBP)
  • Has a negative pregnancy test ≤72 hours before the first dose of study intervention.
  • Has provided an archival or newly-obtained tumor tissue sample adequate for Programmed Cell Death Ligand 1 () testing as determined by central laboratory testing
  • Has a of >3 months
  • Has an (ECOG) performance status of 0 or 1 ≤10 days prior to the first dose of study intervention.

Exclusion criteria

Exclusion Criteria:

Exclusion criteria include, but are not limited to:

  • Has macroscopic residual cSCC after surgery and/or recurrence with active cSCC disease before randomization
  • Has any other histologic type of skin cancer other than invasive cSCC (eg, basal cell carcinoma) that has not been definitively treated with surgery or radiation; Bowen's disease; Merkel cell carcinoma; or melanoma
  • Has received prior therapy with an anti-programmed cell death receptor 1(), anti-PD-L1, or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another costimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
  • Has received prior systemic anticancer therapy including agents for cSCC ≤4 weeks prior to before start of study intervention.
  • Has not recovered from all radiation-related toxicities and has not had radiation pneumonitis
  • Has received a ≤30 days prior to the first dose of study intervention
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has known additional that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Other exceptions may be considered with Sponsor consultation. Note: Participants with low risk early-stage prostate cancer defined as below are not excluded: Stage T1c or T2a with a Gleason score ≤6 and a prostate-specific antigen (≤10 ng/ml) either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to study allocation. Early stage asymptomatic CLL without prior treatment and without any of the risk features (unmutated IGHV, lymphocytes >15,000μL, palpable lymph nodes) will be eligible for the study
  • Has an active disease that has required systemic treatment in past 2 years except replacement therapy (eg, thyroxine, insulin, or physiologic ).
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (HCV; defined as HCV RNA [qualitative] is detected) infection
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
  • Has had an allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Pembrolizumab

    Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.

    Biological: Pembrolizumab

  • Placebo comparator
    Placebo

    Participants receive placebo by IV infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants treated with placebo who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.

    Drug: Placebo

Interventions

  • BiologicalPembrolizumab

    400 mg IV infusion

    Also known as: KEYTRUDA®, MK-3475

  • DrugPlacebo

    Placebo-matched IV infusion

06

What researchers measure

Primary outcomes

  1. Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy

    RFS as assessed by investigator was defined as the time between the date of randomization to the date of first local or regional recurrence of the index lesion, distant metastasis, or death due to any cause; whichever occurred first. Participants were analyzed in the treatment group to which they were randomized. RFS as assessed by investigator is presented.

    Time frame: Up to approximately 62 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is the time from randomization to death due to any cause. Participants were analyzed in the treatment group to which they were randomized. OS is presented.

    Time frame: Up to approximately 62 months

  2. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score is presented.

    Time frame: Baseline and up to approximately 60 months

  3. Change From Baseline in Physical Functioning Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1-5 Score

    Change from baseline in the score of EORTC QLQ-C30 Items 1-5 is reported. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores meant a better level of function. Participants were analyzed in the treatment group to which they were randomized. Change from baseline in EORTC QLQ-C30 physical functioning is presented.

    Time frame: Baseline and up to approximately 60 months

  4. Percentage of Participants Who Experience an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of participants who experience at least one AE is presented.

    Time frame: Up to approximately 62 months

  5. Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of participants who discontinue study treatment due to an AE is presented.

    Time frame: Up to approximately 19 months

07

Results

Posted Jul 22, 2025

Participant flow

Of the 450 participants randomized, 448 received study intervention.

Participant flow — Overall Study
MilestonePembrolizumabPlacebo
Started225225
Treated224224
Switchover to pembrolizumab030
Retreatment with pembrolizumab20
Completed00
Not completed225225
Withdrew: Withdrawal by subject46
Withdrew: Ongoing186194
Withdrew: Lost to follow-up11
Withdrew: Physician decision02
Withdrew: Death3422

Outcome measures

PrimaryRecurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy

RFS as assessed by investigator was defined as the time between the date of randomization to the date of first local or regional recurrence of the index lesion, distant metastasis, or death due to any cause; whichever occurred first. Participants were analyzed in the treatment group to which they were randomized. RFS as assessed by investigator is presented.

Time frame:
Up to approximately 62 months
Reported as:
Median · Months
Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy
MonthsPembrolizumabPlacebo
Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy53.3 (51.3 to NA)53.7 (51.8 to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.07243 (One-sided p-value based on log-rank test stratified by baseline Extracapsular extension (yes versus no) and Cortical bone invasion (yes versus no) with small strata collapsed.) · Hazard ratio (hr): 0.76 · 95% CI 0.53 to 1.10Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by baseline Extracapsular extension (yes versus no) and Cortical bone invasion (yes versus no) with small strata collapsed.
SecondaryOverall Survival (OS)

OS is the time from randomization to death due to any cause. Participants were analyzed in the treatment group to which they were randomized. OS is presented.

Time frame:
Up to approximately 62 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumabPlacebo
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab vs Placebo · Hazard ratio (hr): 1.47 · 95% CI 0.87 to 2.48Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by baseline Extracapsular extension (yes versus no) and Cortical bone invasion (yes versus no) with small strata collapsed.
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score is presented.

Time frame:
Baseline and up to approximately 60 months
Reported as:
Least squares mean · Score on scale
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Score on scalePembrolizumabPlacebo
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score-7.05 (-10.91 to -3.19)-3.64 (-7.74 to 0.47)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.2227 (Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, and stratification factors by Extracapsular extension, Cortical bone invasion, and Prior systemic therapy.) · Mean difference (final values): -3.41 · 95% CI -8.91 to 2.09Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, and stratification factors by Extracapsular extension, Cortical bone invasion, and Prior systemic therapy.
SecondaryChange From Baseline in Physical Functioning Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1-5 Score

Change from baseline in the score of EORTC QLQ-C30 Items 1-5 is reported. The EORTC QLQ-C30 is a cancer specific health-related quality-of life (QoL) questionnaire. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. Higher scores meant a better level of function. Participants were analyzed in the treatment group to which they were randomized. Change from baseline in EORTC QLQ-C30 physical functioning is presented.

Time frame:
Baseline and up to approximately 60 months
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Physical Functioning Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1-5 Score
Scores on a scalePembrolizumabPlacebo
Change From Baseline in Physical Functioning Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1-5 Score-7.60 (-10.56 to -4.63)-4.71 (-7.83 to -1.59)
Statistical analysis
  • Pembrolizumab vs Placebo · Log Rank · p = 0.1874 (Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, and stratification factors by Extracapsular extension, Cortical bone invasion, and Prior systemic therapy.) · Mean difference (final values): -2.89 · 95% CI -7.19 to 1.42Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by study visit interaction, and stratification factors by Extracapsular extension, Cortical bone invasion, and Prior systemic therapy.
SecondaryPercentage of Participants Who Experience an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of participants who experience at least one AE is presented.

Time frame:
Up to approximately 62 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experience an Adverse Event (AE)
Percentage of participantsPembrolizumabPlacebo
Percentage of Participants Who Experience an Adverse Event (AE)94.288.8
SecondaryPercentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the study treatment or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of study treatment, is also an AE. The percentage of participants who discontinue study treatment due to an AE is presented.

Time frame:
Up to approximately 19 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
Percentage of participantsPembrolizumabPlacebo
Percentage of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)10.34.0

Adverse events

Collected over All-cause mortality and adverse events up to approximately 62 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab34/225 (15.1%)55/224 (24.6%)175/224 (78.1%)
Placebo14/225 (6.2%)43/224 (19.2%)143/224 (63.8%)
Pembrolizumab (Retreatment Phase)1/2 (50%)0/2 (0%)2/2 (100%)
Placebo Crossover10/30 (33.3%)15/30 (50%)23/30 (76.7%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventPembrolizumabPlaceboPembrolizumab (Retreatment Phase)Placebo Crossover
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)18/22418/2240/23/30
HyponatraemiaMetabolism and nutrition disorders0/2240/2240/22/30
Acute myocardial infarctionCardiac disorders0/2240/2240/21/30
MyocarditisCardiac disorders0/2240/2240/21/30
PericarditisCardiac disorders0/2240/2240/21/30
MelaenaGastrointestinal disorders0/2240/2240/21/30
COVID-19Infections and infestations1/2241/2240/21/30
Diverticulitis intestinal perforatedInfections and infestations0/2240/2240/21/30
ErysipelasInfections and infestations0/2240/2240/21/30
Head injuryInjury, poisoning and procedural complications1/2240/2240/21/30
Most frequent other events
Showing 10 of 39
Most frequent other events
EventPembrolizumabPlaceboPembrolizumab (Retreatment Phase)Placebo Crossover
Inguinal herniaGastrointestinal disorders1/2240/2241/20/30
NauseaGastrointestinal disorders11/22412/2241/21/30
Blood creatinine increasedInvestigations12/2248/2241/23/30
Decreased appetiteMetabolism and nutrition disorders7/2245/2241/23/30
DysgeusiaNervous system disorders5/2242/2241/21/30
PruritusSkin and subcutaneous tissue disorders42/22418/2240/25/30
FatigueGeneral disorders38/22430/2240/23/30
COVID-19Infections and infestations6/22411/2240/24/30
DiarrhoeaGastrointestinal disorders28/22428/2240/21/30
AstheniaGeneral disorders28/22418/2240/22/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PembrolizumabPlaceboTotal
Mean70.3 ± 10.869.2 ± 10.769.7 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)PembrolizumabPlaceboTotal
Female414182
Male184184368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PembrolizumabPlaceboTotal
Hispanic or Latino464793
Not Hispanic or Latino140148288
Unknown or Not Reported393069
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PembrolizumabPlaceboTotal
American Indian or Alaska Native224
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American022
White174181355
More than one race141125
Unknown or Not Reported352863
Extracapsular Extension
Extracapsular Extension(Participants)PembrolizumabPlaceboTotal
Yes8998187
No135127262
Missing Data101
Cortical Bone Invasion
Cortical Bone Invasion(Participants)PembrolizumabPlaceboTotal
Yes211940
No203206409
Missing101
Prior Systemic Therapy
Prior Systemic Therapy(Participants)PembrolizumabPlaceboTotal
Yes161733
No209208417
08

Study locations

181 sites
  • University of South Alabama, Mitchell Cancer Institute ( Site 1562)
    Mobile, Alabama 36604, United States
  • City of Hope Medical Center ( Site 1505)
    Duarte, California 91010, United States
  • UCSD Moores Cancer Center ( Site 1561)
    La Jolla, California 92093-0698, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568)
    Los Angeles, California 90095, United States
  • University of California Davis Comprehensive Cancer Center ( Site 1560)
    Sacramento, California 95817, United States
  • Stanford University Medical Center ( Site 1503)
    Stanford, California 94305, United States
  • University of Colorado Cancer Center ( Site 1506)
    Aurora, Colorado 80045, United States
  • Smilow Cancer Center at Yale-New Haven ( Site 1507)
    New Haven, Connecticut 06510, United States
  • Boca Raton Regional Hospital ( Site 1551)
    Boca Raton, Florida 33486, United States
  • UF Health ( Site 1511)
    Gainesville, Florida 32608, United States
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1544)
    Miami, Florida 33136, United States
  • Winship Cancer Institute of Emory University ( Site 1512)
    Atlanta, Georgia 30322-1013, United States
  • Indiana University Melvin and Bren Simon Cancer Center ( Site 1515)
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospital and Clinics ( Site 1514)
    Iowa City, Iowa 52242, United States
  • University of Kentucky School of Medicine & Hospitals ( Site 1542)
    Lexington, Kentucky 40536, United States
  • Massachusetts General Hospital ( Site 1518)
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Center ( Site 1519)
    Boston, Massachusetts 02215, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1526)
    Hackensack, New Jersey 07601, United States
  • Northwell Health/ RJ Zuckerberg Cancer Center-Medical Oncology ( Site 1565)
    Lake Success, New York 11042, United States
  • Icahn School of Medicine at Mount Sinai ( Site 1575)
    New York, New York 10029, United States
  • Cleveland Clinic ( Site 1541)
    Cleveland, Ohio 44195, United States
  • Providence Portland Medical Center ( Site 1530)
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center ( Site 1570)
    Pittsburgh, Pennsylvania 15232, United States
  • MUSC Hollings Cancer Center ( Site 1533)
    Charleston, South Carolina 29425, United States
  • West Cancer Center - East Campus ( Site 1535)
    Germantown, Tennessee 38138, United States
  • Vanderbilt Ingram Cancer Center ( Site 1543)
    Nashville, Tennessee 37232, United States
  • The University of Texas-MD Anderson Cancer Center ( Site 1536)
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute ( Site 1537)
    Salt Lake City, Utah 84112, United States
  • Inova Schar Cancer Institute ( Site 1538)
    Fairfax, Virginia 22031, United States
  • West Virginia University ( Site 1569)
    Morgantown, West Virginia 26506, United States
  • Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0028)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1027AAP, Argentina
  • Centro Medico Privado CEMAIC ( Site 0024)
    Capital, Córdoba Province X5008HHW, Argentina
  • Fundacion Estudios Clinicos-Oncology ( Site 0026)
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Centro Oncológico de Rosario ( Site 0003)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Hospital Italiano- Sociedad Italiana de Beneficencia en Buenos Aires ( Site 0009)
    Buenos Aires, C1181ACH, Argentina
  • CEMIC ( Site 0012)
    Buenos Aires, C1431FWO, Argentina
  • Fundacion CIDEA ( Site 0001)
    CABA, C1121ABE, Argentina
  • Centro Oncologico Riojano Integral ( Site 0002)
    La Rioja, F5300COE, Argentina
  • Centro Oncologico Norte ( Site 0023)
    Santiago del Estero, G4200AWD, Argentina
  • Chris OBrien Lifehouse ( Site 0051)
    Camperdown, New South Wales 2050, Australia
  • Lismore Base Hospital ( Site 0050)
    Lismore, New South Wales 2480, Australia
  • Orange Health Services ( Site 0053)
    Orange, New South Wales 2800, Australia
  • Royal North Shore Hospital ( Site 0052)
    St Leonards, New South Wales 2065, Australia
  • Gold Coast University Hospital ( Site 0054)
    Southport, Queensland 4215, Australia
  • Sunshine Coast University Private Hospital-Coastal Cancer Care ( Site 0056)
    Sunshine Coast, Queensland 4575, Australia
  • Alfred Health ( Site 0055)
    Melbourne, Victoria 3004, Australia
  • Oncocentro Ceara ( Site 0108)
    Fortaleza, Ceará 60135-237, Brazil
  • Hospital Erasto Gaertner ( Site 0101)
    Curitiba, Paraná 81520-060, Brazil
  • Hospital Tacchini ( Site 0111)
    Bento Gonçalves, Rio Grande do Sul 95700-084, Brazil
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0100)
    Ijuí, Rio Grande do Sul 98700000, Brazil
  • Hospital Bruno Born ( Site 0107)
    Lajeado, Rio Grande do Sul 95900-000, Brazil
  • Hospital Sao Vicente de Paulo ( Site 0105)
    Passo Fundo, Rio Grande do Sul 99010-080, Brazil
  • Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA-Pesquisa Clinica HC II ( Site 0103)
    Rio de Janeiro, 20220-410, Brazil
  • A. C. Camargo Cancer Center ( Site 0116)
    São Paulo, 01509-010, Brazil
  • Tom Baker Cancer Center ( Site 0161)
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute ( Site 0159)
    Edmonton, Alberta T6G 1Z2, Canada
  • Juravinski Cancer Center ( Site 0151)
    Hamilton, Ontario L8V 1C3, Canada
  • The Ottawa Hospital Cancer Centre ( Site 0154)
    Ottawa, Ontario K1H 8L6, Canada
  • CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 0163)
    Montreal, Quebec H1T 2M4, Canada
  • McGill University Health Centre ( Site 0162)
    Montreal, Quebec H4A 3J1, Canada
  • James Lind Centro de Investigación del Cáncer ( Site 1653)
    Temuco, Araucania 4800827, Chile
  • Enroll SpA ( Site 1654)
    Santiago, Region M. de Santiago 7500587, Chile
  • Bradfordhill ( Site 1651)
    Santiago, Region M. de Santiago 8420383, Chile
  • Bradford Hill Norte ( Site 1652)
    Antofagasta, 1240000, Chile
  • Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0201)
    Bogotá, Bogota D.C. 111411, Colombia
  • Instituto Nacional de Cancerologia E.S.E ( Site 0204)
    Bogotá, Bogota D.C. 111511, Colombia
  • Oncomedica S.A. ( Site 0205)
    Montería, Departamento de Córdoba 230002, Colombia
  • Oncologos del Occidente S.A. ( Site 0206)
    Pereira, Risaralda Department 660001, Colombia
  • Fundación Cardiovascular de Colombia ( Site 0207)
    Piedecuesta, Santander Department 68017, Colombia
  • Fundación Valle del Lili ( Site 0202)
    Cali, Valle del Cauca Department 760032, Colombia
  • Hopital ARCHET 2 ( Site 0356)
    Nice, Alpes-Maritimes 06200, France
  • Hopital Saint Joseph ( Site 0376)
    Marseille, Bouches-du-Rhone 13285, France
  • Hopital La Timone ( Site 0353)
    Marseille, Bouches-du-Rhone 13385, France
  • Centre Hospitalier Universitaire de Caen Normandie-DERMATOLOGY ( Site 0365)
    Caen, Calvados 14000, France
  • CHU Besancon - Hopital Jean Minjoz ( Site 0359)
    Besançon, Doubs 25030, France
  • Centre Hospitalier de Valence ( Site 0377)
    Valence, Drome 26953, France
  • C.H.U. de Nimes. Hopital Caremeau ( Site 0368)
    Nîmes, Gard 30029, France
  • CHU de Bordeaux- Hopital Saint Andre ( Site 0370)
    Bordeaux, Gironde 33075, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0354)
    Toulouse, Haute-Garonne 31059, France
  • Centre Hospitalier Annecy Genevois ( Site 0361)
    Pringy, Haute-Savoie 74374, France
  • CHU Montpellier. ( Site 0367)
    Montpellier, Herault 34295, France
  • CHRU de Lille - Hopital Claude Huriez ( Site 0355)
    Lille, Nord 59037, France
  • CHU Estaing ( Site 0360)
    Clermont-Ferrand, Puy-de-Dome 63003, France
  • CH Lyon Sud Hospices Civils de Lyon ( Site 0350)
    Pierre-Bénite, Rhone 69495, France
  • Hopital Avicenne ( Site 0358)
    Bobigny, Seine-Saint-Denis 93009, France
  • Institut Gustave Roussy ( Site 0352)
    Villejuif, Val-de-Marne 94800, France
  • CHU Poitiers ( Site 0375)
    Poitiers, Vienne 86021, France
  • Universitaetsklinikum Tuebingen ( Site 0409)
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Klinikum Nürnberg Nord ( Site 0415)
    Nuremberg, Bavaria 90419, Germany
  • Universitatsklinikum Giessen und Marburg GmbH ( Site 0413)
    Marburg, Hesse 35043, Germany
  • Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0411)
    Buxtehude, Lower Saxony 21614, Germany
  • Medizinische Hochschule Hannover ( Site 0405)
    Hanover, Lower Saxony 30625, Germany
  • Universitaetsklinikum Essen ( Site 0403)
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitaetsklinikum Berlin - Charite - Campus Mitte ( Site 0400)
    Berlin, 10117, Germany
  • Universitaetsklinikum Hamburg-Eppendorf ( Site 0414)
    Hamburg, 20246, Germany
  • Andreas Syggros Hospital ( Site 0450)
    Athens, Achaia 161 21, Greece
  • Attikon University General Hospital of Athens ( Site 0454)
    Chaïdári, Attica 124 62, Greece
  • Metropolitan Hospital ( Site 0453)
    Neo Faliro, Attica 185 47, Greece
  • Papageorgiou General Hospital ( Site 0451)
    Thessaloniki, 564 03, Greece
  • European Interbalkan Medical Center ( Site 0455)
    Thessaloniki, 570 01, Greece

Showing the first 100 of 181 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2024, 62 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Feb 6, 2019
StartActual
Apr 1, 2019
Primary completionActual
Jun 28, 2024
CompletionActual
Jan 20, 2026
Results first posted
Jul 22, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The study stopped due to futility
changed Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Completed→Terminated
    Why stopped The study stopped due to futility
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03833167
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Apr 1, 2019
Primary completion
Jun 28, 2024
Completion
Jan 20, 2026
Results posted
Jul 22, 2025
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion